Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ajay Wasan

Pain Medicine Pittsburgh, PA Medical Doctor

NPI 1962596163 CMS profile 1272772

5750 Centre Ave Ste 260, Upmc Pain Medicine, Pittsburgh, PA 15206

Open in the dashboard

General payments

$65,965

46 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ajay Wasan of Pittsburgh, PA is reported in the CMS Open Payments database as having received $65,965 across 46 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $26,628 19
2024 General $7,561 5
2023 General $7,353 12
2022 General $12,648 3
2021 General $11,758 6
2019 General $16 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ajay Wasan
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Ajay Wasan were reported at $26,628. Among 95 Pain Medicine profiles paid that year, the median was $405 and the middle half received between $116 and $1,740.

Show as a table
Year Ajay Wasan Pain Medicine median Middle half National median
2019 $16 $298 $103–$1,153 $163
2020 $0 $188 $57–$916 $114
2021 $11,758 $365 $109–$1,150 $132
2022 $12,648 $498 $104–$1,575 $149
2023 $7,353 $334 $108–$1,267 $160
2024 $7,561 $544 $144–$1,302 $164
2025 $26,628 $405 $116–$1,740 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Vertex Pharmaceuticals Incorporated $38,180 25 payments
  2. Jazz Pharmaceuticals Inc. $12,572 1 payment
  3. GW Research Limited $7,633 3 payments
  4. Merck Sharp & Dohme Corporation $7,200 10 payments
  5. Boston Scientific Corporation $263 3 payments
  6. GRT US Holding, Inc. $76 2 payments
  7. Abbott Laboratories $42 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $62,143 16 payments
  2. Travel and Lodging $3,001 13 payments
  3. Food and Beverage $822 17 payments
Products named General payments · program years 2019–2025
  1. Epidiolex $12,572 1 payment
  2. WaveWriter Alpha Prime 16 $134 1 payment
  3. INFINION $112 1 payment
  4. Qutenza $76 2 payments
  5. Protege Family of SCS IPGs $24 1 payment
  6. PROCLAIM $18 1 payment
  7. SPECTRA WAVEWRITER $16 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

1,397

Median for Pain Management: 951

Drug cost

$47,702

Median for Pain Management: $26,034

Branded share of claims

12%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtampza Er Oxycodone Myristate Brand 27 $14,513
Buprenorphine Generic 23 $7,168
Horizant Gabapentin Enacarbil Brand 12 $5,325
Gabapentin Generic 260 $2,968
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 16 $2,829
Duloxetine Hcl Generic 139 $2,763
Pregabalin Generic 105 $1,486
Methadone Hcl Generic 47 $1,457
Baclofen Generic 153 $1,423
Diclofenac Sodium Generic 38 $1,233

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$17,240

Medicare's payments for the services billed

Medicare patients

86

Average age 69

Services billed

328

53 women, 33 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 36%
Diabetes 27%
Ischemic heart disease 26%
Chronic kidney disease 21%
COPD 20%
Heart failure 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

46 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record